Biopharm Asia Intends to Reinstate Listing on OTCBB

Biopharm Asia Intends to Reinstate Listing on OTCBB 
TONGHUA, CHINA -- (Marketwire) -- 11/19/12 --  Biopharm Asia, Inc.
(PINKSHEETS: BFAR) is pleased to announce that Biopharm Asia, Inc.
has finished the audit of the previous two fiscal years' financial
statements. The Company has prepared a 15c 2-11 and is finalizing to
submit it with FINRA no later than end of day, November 19, 2012. 
An approval of 15c 2-11 application allows a market maker to "make a
market" in the Company's stock, conducting principle buy and sell
orders.  
Through discussion with the Market Maker it is the Company's
understanding that FINRA will conduct a review of the 15c 2-11 and
follow up with questions and comments. Typically, FINRA would respond
within 14 days of the filling. The Market Maker will work with the
Company to respond to the questions and comments. Further questions
may be raised by FINRA and the Company will continue to respond until
FINRA has no further questions. Once FINRA is satisfied with the
submission of the 15c 2-11 and the answers to subsequent questions,
the Company would be granted an OTCBB listing. 
With these steps to have its shares reinstated on the OTCBB the
Company is excited to continue its commitment to increasing
transparency, exposure and providing liquidity for its shareholders. 
Safe Harbor
 The information in this release includes forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934. These forward-looking statements, specifically
statements relating to listing and trading on the OTCBB contains
statements about expected future events and/or financial results that
are forward-looking in nature and subject to risks and uncertainties.
Such forward-looking statements by definition involve risks,
uncertainties and other factors, which may cause the actual results,
performance or achievements of Biopharm Asia to be materially
different from the statements made herein. Although the Company
believes that its expectations are based on reasonable assumptions,
actual results may differ materially.  
Contact Information
Contact:
Biopharm Asia, Inc.
Investor Relations
(86)130-2919-4689 
 
 
Press spacebar to pause and continue. Press esc to stop.